bioAffinity Technologies, Inc. Files Form 8-K: Key Details Investors Should Know

San Antonio, TX, March 6, 2026 — bioAffinity Technologies, Inc. (“the Company”), a San Antonio-based biotechnology firm, has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC). While the filing itself appears to be a routine update, investors should examine the document closely to understand the current regulatory status and any implications for the Company’s capital market standing.

Key Points from the Filing

• Form Type: The Company has filed an 8-K Current Report with the SEC, pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The date of the report is March 5, 2026.
• Company Information:
  • Name: bioAffinity Technologies, Inc.
  • Address: 3300 Nacogdoches Road, Suite 216, San Antonio, TX 78217
  • Phone: 210-698-5334
• Securities Registered:
  • Common Stock (par value \$0.007 per share) — Trading Symbol: BIAF — Listed on NASDAQ Capital Market
  • Warrants to Purchase Common Stock — Trading Symbol: BIAFW — Also listed on NASDAQ Capital Market
• Emerging Growth Company Status: The Company has checked as an Emerging Growth Company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. This status can allow for certain reduced regulatory and reporting requirements, potentially making it easier to access capital.
• Other Compliance Matters:
  • The Company has not filed this 8-K in connection with written communications (Rule 425), soliciting material (Rule 14a-12), or pre-commencement tender offers (Rules 14d-2(b) or 13e-4(c)). All such boxes are unchecked.
  • The Company has not elected to use the extended transition period for complying with new or revised financial accounting standards.
• Signature: The Form 8-K is signed on behalf of bioAffinity Technologies, Inc. on March 6, 2026.

Analysis & Potential Price Sensitivity

On review, the filing does not contain material news, change in business operations, executive changes, financial results, or any event likely to immediately affect the share price. The 8-K appears to be a standard compliance and corporate update, confirming the Company’s securities registration and current reporting and listing status on the NASDAQ.

There are no disclosures of mergers, acquisitions, financial restatements, regulatory investigations, or other events typically considered price-sensitive. The reaffirmation of the Company’s Emerging Growth Company status and its securities’ continued listing on the NASDAQ may offer some reassurance to shareholders, but this is not new information.

What Should Shareholders Know?

• No New Price-Sensitive Events: There is no indication of significant new developments or events that would be expected to move the share price in the near term.
• Ongoing NASDAQ Listing: Both common stock and warrants remain listed and in good standing on the NASDAQ Capital Market.
• Emerging Growth Company: The status is retained, which may allow for cost savings and flexibility, but does not constitute a new development.

Conclusion

While the Form 8-K filing by bioAffinity Technologies, Inc. is important in maintaining transparency and compliance with SEC rules, it does not include any material or price-sensitive information that would be expected to impact the Company’s share price at this time. Investors should continue to monitor future filings for substantive updates that may affect the Company’s valuation or strategic direction.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult a financial advisor before making investment decisions. The author and publisher assume no responsibility or liability for any actions taken based on the information provided herein.

View bioAffinity Technologies, Inc. Historical chart here